OncoMatch/Clinical Trials/NCT05808634
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Is NCT05808634 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies BA3182 for advanced adenocarcinoma.
Treatment: BA3182 — The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Adequate hematological function
Kidney function
Adequate renal function
Liver function
Adequate liver function
Adequate renal function; Adequate liver function; Adequate hematological function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Irvine · Irvine, California
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- Yale Cancer Center · New Haven, Connecticut
- Northwestern University · Chicago, Illinois
- University of Illinois · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05808634 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify